Update
$Syndax Pharmaceuticals(SNDX.US$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
